AI-Discovered Drug Reverses Aging Markers In Study, Biotech Says
Six proteomic clocks from independent groups all found younger biological age in 42 treated patients, while lung function improved dose dependently, researchers said.
9 Articles
9 Articles
Insilico says its AI-designed lung drug lowered biological age markers in a 42-patient trial
Blood samples from a small lung-disease trial have been run through six independently built ageing clocks, and all six returned the same answer: the patients on the drug looked biologically younger than the patients on placebo. “More lifetimes than humanity lost in all the wars ever fought. If you manage to add 3 years to […] This story continues at The Next Web
The experimental Rent-Sertib drug developed with I.E. showed a decline in the biological age of patients.
Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment). First Universal Consensus Across Six Independently-Developed Proteomic Aging Clocks: Analyzing 12-week longitudinal Olink proteomic data from 42 IPF patients, …
AI-Discovered Drug Reverses Aging Markers In Study, Biotech Says
An experimental lung disease drug developed using artificial intelligence showed promise in reversing biological signs of aging, pointing to broader potential use of the treatment, according to its developer.
Six proteomic clocks developed by independent teams coincided with a lower biological age sign among patients treated with rentosertib, a drug created with artificial intelligence platforms. The result, observed in a Phase IIa trial against idiopathic pulmonary fibrosis, is promising, although its own authors warn that it still does not allow to demonstrate a general reversal of aging. *** Six models recorded a lower biological age in the groups…
NewLimit Says Its AI System Reversed Aging Signs in Human Liver Cells
NewLimit, the longevity biotech backed by Coinbase CEO Brian Armstrong, says its AI system Ambrosia reprogrammed old human liver cells to behave like young ones again. Investors just backed the claim with a $435 million Series C that pushed the company's valuation to $3.1 billion, even though the data hasn't been peer reviewed and human trials don't start until 2027.
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
